International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers

Kelly A. Metcalfe, Daphna Birenbaum-Carmeli, Jan Lubinski, Jacek Gronwald, Henry Lynch, Pal Moller, Parviz Ghadirian, William D. Foulkes, Jan Klijn, Eitan Friedman, Charmaine Kim-Sing, Peter Ainsworth, Barry Rosen, Susan Domchek, Teresa Wagner, Nadine Tung, Siranoush Manoukian, Fergus J Couch, Ping Sun, Steven A. NarodM. Daly, H. M. Saal, K. Sweet, Dominique Lyonnet, A. Eisen, G. Rennen, J. McLennan, R. Gershoni-Baruch, J. Garber, S. Cummings, J. Weitzel, B. Karlan, R. N. Kurz, W. McKinnon, M. Wood, D. Gilchrist, A. Chudley, M. Osborne, David Fishman, W. S. Meschino, E. Lemire, C. Maugard, G. Mills, S. Merajver, D. Rayson, J. M. Collee

Research output: Contribution to journalArticle

233 Citations (Scopus)

Abstract

Several options for cancer prevention are available for women with a BRCA1 or BRCA2 mutation, including prophylactic surgery, chemoprevention and screening. The authors report on preventive practices in women with mutations from 9 countries and examine differences in uptake according to country. Women with a BRCA1 or BRCA2 mutation were contacted after receiving their genetic test result and were questioned regarding their preventive practices. Information was recorded on prophylactic mastectomy, prophylactic oophorectomy, use of tamoxifen and screening (MRI and mammography). Two thousand six hundred seventy-seven women with a BRCA1 or BRCA2 mutation from 9 countries were included. The follow-up questionnaire was completed a mean of 3.9 years (range 1.5-10.3 years) after genetic testing. One thousand five hundred thirty-one women (57.2%) had a bilateral prophylactic oophorectomy. Of the 1,383 women without breast cancer, 248 (18.0%) had had a prophylactic bilateral mastectomy. Among those who did not have a prophylactic mastectomy, only 76 women (5.5%) took tamoxifen and 40 women (2.9%) took raloxifene for breast cancer prevention. Approximately one-half of the women at risk for breast cancer had taken no preventive option, relying solely on screening. There were large differences in the uptake of the different preventive options by country of residence. Prophylactic oophorectomy is now generally accepted by women and their physicians as a cancer preventive measure. However, only the minority of women with a BRCA1 or BRCA2 mutation opt for prophylactic mastectomy or take tamoxifen for the prevention of hereditary breast cancer. Approximately one-half of women at risk for breast cancer rely on screening alone.

Original languageEnglish (US)
Pages (from-to)2017-2022
Number of pages6
JournalInternational Journal of Cancer
Volume122
Issue number9
DOIs
StatePublished - May 1 2008

Fingerprint

Mutation
Breast Neoplasms
Ovariectomy
Tamoxifen
Women Physicians
Chemoprevention
Genetic Testing
Mammography
Neoplasms
Prophylactic Mastectomy

Keywords

  • BRCA1
  • BRCA2
  • Breast cancer
  • Ovarian cancer
  • Prevention

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Metcalfe, K. A., Birenbaum-Carmeli, D., Lubinski, J., Gronwald, J., Lynch, H., Moller, P., ... Collee, J. M. (2008). International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer, 122(9), 2017-2022. https://doi.org/10.1002/ijc.23340

International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. / Metcalfe, Kelly A.; Birenbaum-Carmeli, Daphna; Lubinski, Jan; Gronwald, Jacek; Lynch, Henry; Moller, Pal; Ghadirian, Parviz; Foulkes, William D.; Klijn, Jan; Friedman, Eitan; Kim-Sing, Charmaine; Ainsworth, Peter; Rosen, Barry; Domchek, Susan; Wagner, Teresa; Tung, Nadine; Manoukian, Siranoush; Couch, Fergus J; Sun, Ping; Narod, Steven A.; Daly, M.; Saal, H. M.; Sweet, K.; Lyonnet, Dominique; Eisen, A.; Rennen, G.; McLennan, J.; Gershoni-Baruch, R.; Garber, J.; Cummings, S.; Weitzel, J.; Karlan, B.; Kurz, R. N.; McKinnon, W.; Wood, M.; Gilchrist, D.; Chudley, A.; Osborne, M.; Fishman, David; Meschino, W. S.; Lemire, E.; Maugard, C.; Mills, G.; Merajver, S.; Rayson, D.; Collee, J. M.

In: International Journal of Cancer, Vol. 122, No. 9, 01.05.2008, p. 2017-2022.

Research output: Contribution to journalArticle

Metcalfe, KA, Birenbaum-Carmeli, D, Lubinski, J, Gronwald, J, Lynch, H, Moller, P, Ghadirian, P, Foulkes, WD, Klijn, J, Friedman, E, Kim-Sing, C, Ainsworth, P, Rosen, B, Domchek, S, Wagner, T, Tung, N, Manoukian, S, Couch, FJ, Sun, P, Narod, SA, Daly, M, Saal, HM, Sweet, K, Lyonnet, D, Eisen, A, Rennen, G, McLennan, J, Gershoni-Baruch, R, Garber, J, Cummings, S, Weitzel, J, Karlan, B, Kurz, RN, McKinnon, W, Wood, M, Gilchrist, D, Chudley, A, Osborne, M, Fishman, D, Meschino, WS, Lemire, E, Maugard, C, Mills, G, Merajver, S, Rayson, D & Collee, JM 2008, 'International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers', International Journal of Cancer, vol. 122, no. 9, pp. 2017-2022. https://doi.org/10.1002/ijc.23340
Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer. 2008 May 1;122(9):2017-2022. https://doi.org/10.1002/ijc.23340
Metcalfe, Kelly A. ; Birenbaum-Carmeli, Daphna ; Lubinski, Jan ; Gronwald, Jacek ; Lynch, Henry ; Moller, Pal ; Ghadirian, Parviz ; Foulkes, William D. ; Klijn, Jan ; Friedman, Eitan ; Kim-Sing, Charmaine ; Ainsworth, Peter ; Rosen, Barry ; Domchek, Susan ; Wagner, Teresa ; Tung, Nadine ; Manoukian, Siranoush ; Couch, Fergus J ; Sun, Ping ; Narod, Steven A. ; Daly, M. ; Saal, H. M. ; Sweet, K. ; Lyonnet, Dominique ; Eisen, A. ; Rennen, G. ; McLennan, J. ; Gershoni-Baruch, R. ; Garber, J. ; Cummings, S. ; Weitzel, J. ; Karlan, B. ; Kurz, R. N. ; McKinnon, W. ; Wood, M. ; Gilchrist, D. ; Chudley, A. ; Osborne, M. ; Fishman, David ; Meschino, W. S. ; Lemire, E. ; Maugard, C. ; Mills, G. ; Merajver, S. ; Rayson, D. ; Collee, J. M. / International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. In: International Journal of Cancer. 2008 ; Vol. 122, No. 9. pp. 2017-2022.
@article{bc58e9952c9e48a582f2720b1a17bc18,
title = "International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers",
abstract = "Several options for cancer prevention are available for women with a BRCA1 or BRCA2 mutation, including prophylactic surgery, chemoprevention and screening. The authors report on preventive practices in women with mutations from 9 countries and examine differences in uptake according to country. Women with a BRCA1 or BRCA2 mutation were contacted after receiving their genetic test result and were questioned regarding their preventive practices. Information was recorded on prophylactic mastectomy, prophylactic oophorectomy, use of tamoxifen and screening (MRI and mammography). Two thousand six hundred seventy-seven women with a BRCA1 or BRCA2 mutation from 9 countries were included. The follow-up questionnaire was completed a mean of 3.9 years (range 1.5-10.3 years) after genetic testing. One thousand five hundred thirty-one women (57.2{\%}) had a bilateral prophylactic oophorectomy. Of the 1,383 women without breast cancer, 248 (18.0{\%}) had had a prophylactic bilateral mastectomy. Among those who did not have a prophylactic mastectomy, only 76 women (5.5{\%}) took tamoxifen and 40 women (2.9{\%}) took raloxifene for breast cancer prevention. Approximately one-half of the women at risk for breast cancer had taken no preventive option, relying solely on screening. There were large differences in the uptake of the different preventive options by country of residence. Prophylactic oophorectomy is now generally accepted by women and their physicians as a cancer preventive measure. However, only the minority of women with a BRCA1 or BRCA2 mutation opt for prophylactic mastectomy or take tamoxifen for the prevention of hereditary breast cancer. Approximately one-half of women at risk for breast cancer rely on screening alone.",
keywords = "BRCA1, BRCA2, Breast cancer, Ovarian cancer, Prevention",
author = "Metcalfe, {Kelly A.} and Daphna Birenbaum-Carmeli and Jan Lubinski and Jacek Gronwald and Henry Lynch and Pal Moller and Parviz Ghadirian and Foulkes, {William D.} and Jan Klijn and Eitan Friedman and Charmaine Kim-Sing and Peter Ainsworth and Barry Rosen and Susan Domchek and Teresa Wagner and Nadine Tung and Siranoush Manoukian and Couch, {Fergus J} and Ping Sun and Narod, {Steven A.} and M. Daly and Saal, {H. M.} and K. Sweet and Dominique Lyonnet and A. Eisen and G. Rennen and J. McLennan and R. Gershoni-Baruch and J. Garber and S. Cummings and J. Weitzel and B. Karlan and Kurz, {R. N.} and W. McKinnon and M. Wood and D. Gilchrist and A. Chudley and M. Osborne and David Fishman and Meschino, {W. S.} and E. Lemire and C. Maugard and G. Mills and S. Merajver and D. Rayson and Collee, {J. M.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1002/ijc.23340",
language = "English (US)",
volume = "122",
pages = "2017--2022",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers

AU - Metcalfe, Kelly A.

AU - Birenbaum-Carmeli, Daphna

AU - Lubinski, Jan

AU - Gronwald, Jacek

AU - Lynch, Henry

AU - Moller, Pal

AU - Ghadirian, Parviz

AU - Foulkes, William D.

AU - Klijn, Jan

AU - Friedman, Eitan

AU - Kim-Sing, Charmaine

AU - Ainsworth, Peter

AU - Rosen, Barry

AU - Domchek, Susan

AU - Wagner, Teresa

AU - Tung, Nadine

AU - Manoukian, Siranoush

AU - Couch, Fergus J

AU - Sun, Ping

AU - Narod, Steven A.

AU - Daly, M.

AU - Saal, H. M.

AU - Sweet, K.

AU - Lyonnet, Dominique

AU - Eisen, A.

AU - Rennen, G.

AU - McLennan, J.

AU - Gershoni-Baruch, R.

AU - Garber, J.

AU - Cummings, S.

AU - Weitzel, J.

AU - Karlan, B.

AU - Kurz, R. N.

AU - McKinnon, W.

AU - Wood, M.

AU - Gilchrist, D.

AU - Chudley, A.

AU - Osborne, M.

AU - Fishman, David

AU - Meschino, W. S.

AU - Lemire, E.

AU - Maugard, C.

AU - Mills, G.

AU - Merajver, S.

AU - Rayson, D.

AU - Collee, J. M.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Several options for cancer prevention are available for women with a BRCA1 or BRCA2 mutation, including prophylactic surgery, chemoprevention and screening. The authors report on preventive practices in women with mutations from 9 countries and examine differences in uptake according to country. Women with a BRCA1 or BRCA2 mutation were contacted after receiving their genetic test result and were questioned regarding their preventive practices. Information was recorded on prophylactic mastectomy, prophylactic oophorectomy, use of tamoxifen and screening (MRI and mammography). Two thousand six hundred seventy-seven women with a BRCA1 or BRCA2 mutation from 9 countries were included. The follow-up questionnaire was completed a mean of 3.9 years (range 1.5-10.3 years) after genetic testing. One thousand five hundred thirty-one women (57.2%) had a bilateral prophylactic oophorectomy. Of the 1,383 women without breast cancer, 248 (18.0%) had had a prophylactic bilateral mastectomy. Among those who did not have a prophylactic mastectomy, only 76 women (5.5%) took tamoxifen and 40 women (2.9%) took raloxifene for breast cancer prevention. Approximately one-half of the women at risk for breast cancer had taken no preventive option, relying solely on screening. There were large differences in the uptake of the different preventive options by country of residence. Prophylactic oophorectomy is now generally accepted by women and their physicians as a cancer preventive measure. However, only the minority of women with a BRCA1 or BRCA2 mutation opt for prophylactic mastectomy or take tamoxifen for the prevention of hereditary breast cancer. Approximately one-half of women at risk for breast cancer rely on screening alone.

AB - Several options for cancer prevention are available for women with a BRCA1 or BRCA2 mutation, including prophylactic surgery, chemoprevention and screening. The authors report on preventive practices in women with mutations from 9 countries and examine differences in uptake according to country. Women with a BRCA1 or BRCA2 mutation were contacted after receiving their genetic test result and were questioned regarding their preventive practices. Information was recorded on prophylactic mastectomy, prophylactic oophorectomy, use of tamoxifen and screening (MRI and mammography). Two thousand six hundred seventy-seven women with a BRCA1 or BRCA2 mutation from 9 countries were included. The follow-up questionnaire was completed a mean of 3.9 years (range 1.5-10.3 years) after genetic testing. One thousand five hundred thirty-one women (57.2%) had a bilateral prophylactic oophorectomy. Of the 1,383 women without breast cancer, 248 (18.0%) had had a prophylactic bilateral mastectomy. Among those who did not have a prophylactic mastectomy, only 76 women (5.5%) took tamoxifen and 40 women (2.9%) took raloxifene for breast cancer prevention. Approximately one-half of the women at risk for breast cancer had taken no preventive option, relying solely on screening. There were large differences in the uptake of the different preventive options by country of residence. Prophylactic oophorectomy is now generally accepted by women and their physicians as a cancer preventive measure. However, only the minority of women with a BRCA1 or BRCA2 mutation opt for prophylactic mastectomy or take tamoxifen for the prevention of hereditary breast cancer. Approximately one-half of women at risk for breast cancer rely on screening alone.

KW - BRCA1

KW - BRCA2

KW - Breast cancer

KW - Ovarian cancer

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=40749132232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40749132232&partnerID=8YFLogxK

U2 - 10.1002/ijc.23340

DO - 10.1002/ijc.23340

M3 - Article

C2 - 18196574

AN - SCOPUS:40749132232

VL - 122

SP - 2017

EP - 2022

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 9

ER -